These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 912313)

  • 1. Interaction between azapropazone and warfarin.
    McElnay JC; D'Arcy PF
    Br Med J; 1977 Sep; 2(6089):773-4. PubMed ID: 912313
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin.
    Urien S; Albengres E; Pinquier JL; Tillement JP
    Clin Pharmacol Ther; 1986 Jun; 39(6):683-9. PubMed ID: 3709033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between azapropazone and warfarin.
    McElnay JC; D'Arcy PF
    Experientia; 1978 Oct; 34(10):1320-1. PubMed ID: 738406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone.
    Fehske KJ; Schläfer U; Wollert U; Müller WE
    Mol Pharmacol; 1982 Mar; 21(2):387-93. PubMed ID: 6808349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-affinity binding of ethacrynic acid is mediated by the two most important drug binding sites of human serum albumin.
    Fehske KJ; Müller WE
    Pharmacology; 1986; 32(4):208-13. PubMed ID: 3714803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-binding properties of rat alpha 1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid.
    Hervé F; Rajkowski K; Martin MT; Dessen P; Cittanova N
    Biochem J; 1984 Jul; 221(2):401-6. PubMed ID: 6206846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of azapropazone in chronic renal and hepatic failure.
    Breuing KH; Gilfrich HJ; Meinertz T; Wiegand UW; Jähnchen E
    Eur J Clin Pharmacol; 1981; 20(2):147-55. PubMed ID: 7262176
    [No Abstract]   [Full Text] [Related]  

  • 8. Azapropazone binding to human serum albumin.
    Fehske KJ; Jähnchen E; Müller WE; Stillbauer A
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Aug; 313(2):159-63. PubMed ID: 7422015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of azapropazone following single oral and intravenous doses.
    Breuing KH; Gilfrich HJ; Meinertz T; Jähnchen E
    Arzneimittelforschung; 1979; 29(6):971-2. PubMed ID: 582795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of azapropazone in the elderly.
    Ritch AE; Perera WN; Jones CJ
    Br J Clin Pharmacol; 1982 Jul; 14(1):116-9. PubMed ID: 7104163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of azapropazone on the binding of warfarin to human serum proteins [proceedings].
    McElnay JC; D'Arcy PF
    J Pharm Pharmacol; 1978 Dec; 30 Suppl():73P. PubMed ID: 32332
    [No Abstract]   [Full Text] [Related]  

  • 12. A re-evaluation of the HSA-piroxicam interaction.
    Brée F; Urien S; Nguyen P; Riant P; Albengres E; Tillement JP
    Eur J Drug Metab Pharmacokinet; 1990; 15(4):303-7. PubMed ID: 2088766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration of azapropazone in synovial tissues and fluid.
    Spahn H; Thabe K; Mutschler E; Tillmann K; Gikalov I
    Eur J Clin Pharmacol; 1987; 32(3):303-7. PubMed ID: 3595703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between azapropazone and warfarin.
    Powell-Jackson PR
    Br Med J; 1977 May; 1(6070):1193-4. PubMed ID: 861532
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands.
    Kragh-Hansen U
    Mol Pharmacol; 1988 Aug; 34(2):160-71. PubMed ID: 3412320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Human pharmacokinetics of different i.v. doses of azapropazone (HPLC-determination) (author's transl)].
    Gikalov I; Kaufmann R; Schuster O
    Arzneimittelforschung; 1982; 32(4):423-6. PubMed ID: 7201814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of azapropazone and its principal 8-hydroxy-metabolite in plasma, urine and gastrointestinal mucosa determined by HPLC.
    Rainsford KD
    J Pharm Pharmacol; 1985 May; 37(5):341-5. PubMed ID: 2862244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic investigation of the interaction of azapropazone with phenytoin.
    Geaney DP; Carver JG; Davies CL; Aronson JK
    Br J Clin Pharmacol; 1983 Jun; 15(6):727-34. PubMed ID: 6871071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma protein binding of azapropazone in patients with kidney and liver disease.
    Jähnchen E; Blanck KJ; Breuing KH; Gilfrich HJ; Meinertz T; Trenk D
    Br J Clin Pharmacol; 1981 Apr; 11(4):361-7. PubMed ID: 7259929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of warfarin by azapropazone.
    Green AE; Hort JF; Korn HE; Leach H
    Br Med J; 1977 Jun; 1(6075):1532. PubMed ID: 871646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.